R&D News | pharmaphorum

News

abstract shapes, bone structure, 3d render, bone

UK biotech Mereo gears up for key brittle bone drug data

UK biotech Mereo BioPharma is hoping the coming months will transform its fortunes as it prepares for potentially pivotal data for a brittle bone disease drug.

News

Nimble Therapeutics spins out of Roche to focus on peptide R...

US biotech Nimble Therapeutics has announced it is operating as a standalone business after spinning out from Roche, focusing on drug R&D based around peptides.

News

Lynparza on cusp of approval for advanced ovarian cancer

Breast cancer drug Lynparza (olaparib) is poised for EU approval for the first-line treatment of a certain type of metastatic ovarian cancer.

News

Blow for Gilead as another NASH trial fails

Gilead's attempts to find a treatment for nonalcoholic steatohepatitis (NASH) have been dealt another blow after another trial failure for one of its prime candidates to treat the disease.<

News

UK government hopes CRO cash will boost life sciences

Research and development in the UK will have a major boost thanks to the Medicines Discovery Catapult today launching 22 partnerships with UK-based contract research organisations (CRO

News

Biogen's R&D strategy fails to impress after Alzheimer's tri...

The dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s drug aducanumab, and in its latest Q1 figures the company hoped

UK biotech Mereo gears up for key brittle bone drug data

Nimble Therapeutics spins out of Roche to focus on peptide R...

Lynparza on cusp of approval for advanced ovarian cancer

Blow for Gilead as another NASH trial fails

UK government hopes CRO cash will boost life sciences

Biogen's R&D strategy fails to impress after Alzheimer's tri...

Electra sets terms for IPO, hoping to raise up to $347m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks